Cerus Corp CERS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Cerus Corporation to Participate in Upcoming Investor Conferences
Cerus Corporation to Participate in the 17th Annual Craig-Hallum Alpha Select Conference
Cerus Corporation Announces Third Quarter 2026 Financial Results
Cerus Corporation Announces Positive Topline Results from Phase 3 RedeS Trial of the INTERCEPT Blood System for Red Blood Cells
Cerus Corporation to Release Third Quarter 2026 Financial Results on November 2, 2026
Cerus Corporation Announces Workshop and Abstracts at the 2026 AABB Annual Meeting
Trading Information
- Previous Close Price
- $1.86
- Day Range
- $1.84–1.94
- 52-Week Range
- $1.47–3.47
- Bid/Ask
- $1.85 / $1.97
- Shares Outstanding
- 201.95M
- Market Cap
- $383.71M
- Volume/Avg
- 5M / 2M
Key Statistics
- Price/Earnings (Normalized)
- 46.45
- Price/Sales
- 1.65
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety, and generates revenue from the same.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Core
- Total Number of Employees
- 345
- Website
- https://www.cerus.com
Valuation
Metric | CERS |
|---|---|
Price/Earnings (Normalized) | 46.45 |
Price/Book Value | 5.05 |
Price/Sales | 1.65 |
Price/Cash Flow | 19.92 |
Price/Earnings
CERS
Financial Strength
Metric | CERS |
|---|---|
Quick Ratio | 1.10 |
Current Ratio | 1.96 |
Interest Coverage | −0.03 |
Quick Ratio
CERS
Profitability
Metric | CERS |
|---|---|
Return on Assets (Normalized) | 3.99% |
Return on Equity (Normalized) | 12.59% |
Return on Invested Capital (Normalized) | 8.63% |
Return on Assets
CERS
Medical Devices Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Abbott Laboratories ABT | LOCK|qLY>%N | LOCK|q<RB | $181B | |||
| Medtronic PLC MDT | LOCK|#z^wg#@ | LOCK|j%Yf# | $131B | |||
| Stryker Corp SYK | LOCK|yT!cfb@Z | LOCK|d%p | $121B | |||
| Boston Scientific Corp BSX | LOCK|h>Q$Y$ | LOCK|&m%? | $62B | |||
| Edwards Lifesciences Corp EW | LOCK|YRD!!h$ | LOCK|&SKlM | $61B | |||
| GE HealthCare Technologies Inc Common Stock GEHC | LOCK|Tt?mb@ | LOCK|TQ | $37B | |||
| DexCom Inc DXCM | LOCK|?&%^SR# | LOCK|#@#&n | $31B | |||
| Koninklijke Philips NV ADR PHG | LOCK|K>f | LOCK|VNw | $29B | |||
| Steris PLC STE | LOCK|^kp>%G$ | LOCK|#>^C | $25B | |||
| Zimmer Biomet Holdings Inc ZBH | LOCK|<k?nwjD | LOCK|p$? | $19B |